We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+52.98%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
+$345M
Cap. Flow
-$93M
Cap. Flow %
-5.67%
Top 10 Hldgs %
55.29%
Holding
48
New
7
Increased
7
Reduced
22
Closed
11
Avg Time Held
1.1 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
0.6 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$617M
$177M 10.81%
9,731,341
+2,083,073
+27% +$30.9M
2021 Q1
21 quarters
AKTS icon
2
Aktis Oncology
AKTS
$902M
$156M 9.5%
4,835,872
– –
2026 Q1
1 quarter
LQDA icon
3
Liquidia
LQDA
$5.08B
$111M 6.74%
1,386,174
-18,984
-1% -$1.02M
2025 Q3
3 quarters
RVMD icon
4
Revolution Medicines
RVMD
$36.1B
$92.2M 5.62%
492,483
-14,293
-3% -$2.09M
2021 Q3
19 quarters
CORT icon
5
Corcept Therapeutics
CORT
$7.48B
$67M 4.09%
771,028
-214,672
-22% -$13M
2026 Q1
1 quarter
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.78B
$65.9M 4.02%
1,620,780
-39,916
-2% -$1.38M
2024 Q1
9 quarters
TVTX icon
7
Travere Therapeutics
TVTX
$4.77B
$63.8M 3.89%
1,122,731
-10,634
-0.9% -$471K
2026 Q1
1 quarter
DBVT icon
8
DBV Technologies
DBVT
$645M
$60.1M 3.67%
3,666,284
-1,547,077
-30% -$29.2M
2025 Q2
4 quarters
TRVI icon
9
Trevi Therapeutics
TRVI
$1.89B
$57.3M 3.5%
3,073,577
-224,853
-7% -$3.27M
2024 Q1
9 quarters
ALMS icon
10
Alumis
ALMS
$667M
$56.8M 3.46%
2,019,020
-367,509
-15% -$8.55M
2025 Q4
2 quarters
QURE icon
11
uniQure
QURE
$1.53B
$56.5M 3.44%
1,225,855
-143,376
-10% -$3.75M
2025 Q4
2 quarters
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$1.62B
$47.4M 2.89%
+1,418,215
New +$35.2M
2026 Q2
0 quarters
RLAY icon
13
Relay Therapeutics
RLAY
$3.82B
$45.2M 2.76%
2,415,672
+56,086
+2% +$814K
2023 Q1
13 quarters
ABVX icon
14
Abivax
ABVX
$7.32B
$44.8M 2.73%
336,347
+229,079
+214% +$25.9M
2025 Q4
2 quarters
DYN icon
15
Dyne Therapeutics
DYN
$3.13B
$42.7M 2.6%
1,922,093
+513,941
+36% +$9.6M
2025 Q2
4 quarters
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.04B
$40.9M 2.5%
420,002
-3,980
-0.9% -$348K
2026 Q1
1 quarter
BIOA icon
17
BioAge Labs
BIOA
$240M
$40.9M 2.49%
+1,667,661
New +$30.1M
2026 Q2
0 quarters
URGN icon
18
UroGen Pharma
URGN
$1.38B
$34.3M 2.09%
933,415
-10,388
-1% -$282K
2025 Q3
3 quarters
MLTX icon
19
MoonLake Immunotherapeutics
MLTX
$998M
$31.3M 1.91%
1,606,967
-204,115
-11% -$3.7M
2026 Q1
1 quarter
PVLA icon
20
Palvella Therapeutics
PVLA
$2.11B
$31.2M 1.9%
204,027
-2,377
-1% -$289K
2025 Q3
3 quarters
TSHA icon
21
Taysha Gene Therapies
TSHA
$1.32B
$30.6M 1.87%
+4,500,000
New +$26.6M
2026 Q2
0 quarters
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$822M
$29.2M 1.78%
1,333,523
-7,210
-0.5% -$150K
2025 Q3
3 quarters
GLUE icon
23
Monte Rosa Therapeutics
GLUE
$783M
$28.1M 1.71%
1,161,081
-15,847
-1% -$299K
2025 Q4
2 quarters
ZURA icon
24
Zura Bio
ZURA
$104M
$26.4M 1.61%
+4,472,843
New +$21.3M
2026 Q2
0 quarters
NTRA icon
25
Natera
NTRA
$41.8B
$25.1M 1.53%
92,638
-436
-0.5% -$93K
2024 Q1
9 quarters

Similar funds

MPM BioImpact's Q2 2026 Portfolio in Review

As of Q2 2026, MPM BioImpact held 48 positions worth $1.64B, up 27% from $1.29B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

MPM BioImpact withdrew a net $93M in Q2 2026, closing 11 positions and reducing 22 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM BioImpact opened a new position in Ultragenyx Pharmaceutical worth $47.4M.

  • MPM BioImpact's largest Q2 2026 buy was Ultragenyx Pharmaceutical: 1,418,215 shares worth $47.4M.
  • MPM BioImpact added most to Cullinan Therapeutics in Q2 2026, an estimated $30.9M increase.
  • MPM BioImpact's biggest Q2 2026 reduction was DBV Technologies, cutting an estimated $29.2M.
  • MPM BioImpact fully exited Agios Pharmaceuticals in Q2 2026, selling an estimated $44.2M.
  • MPM BioImpact's ten largest holdings make up 55% of its $1.64B portfolio in Q2 2026.
  • MPM BioImpact opened 7 new positions and closed 11 in Q2 2026.
  • MPM BioImpact's portfolio value rose 27% quarter-over-quarter to $1.64B.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.